Gepefrine
group of stereoisomers
Gepefrine, also known as 3-hydroxyamphetamine or α-methyl-meta-tyramine and sold under the brand names Pressionorm and Wintonin, is a sympathomimetic medication used as an antihypotensive agent which has been marketed in Germany.
Pharmacology
Gepefrine is described as a sympathomimetic and antihypotensive agent.
Chemistry
Gepefrine, also known as 3-hydroxy-α-methylphenethylamine or as 3-hydroxyamphetamine, is a substituted phenethylamine and amphetamine derivative. It is used pharmaceutically as the (S)-enantiomer and as the tartrate salt. Related compounds include meta-tyramine (3-hydroxyphenethylamine), 4-hydroxyamphetamine (norpholedrine), 3,4-dihydroxyamphetamine (α-methyldopamine), and metaraminol ((1R,2S)-3,β-dihydroxyamphetamine), among others.
History
Gepefrine was synthesized by 1968 and was introduced for medical use in Germany by 1981.
Society and culture
Names
Gepefrine is the generic name of the drug and its INNTooltip International Nonproprietary Name. Brand names of gepefrine include Pressionorm and Wintonin.
Other drugs
Gepefrine is a known metabolite of amphetamine in rats.
This brief starts where responsible research should: with the source description of “Gepefrine” as group of stereoisomers. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as group of stereoisomers. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 4, 2026. The linked authority identifier is Q5548658. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1968 and 1981.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Gepefrine”, its source revision and the description used here.
- Expand the search: follow Gepefrine primary sources, Gepefrine archive and Gepefrine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Gepefrine”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Gepefrine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.